Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab Monotherapy in Adolescents with Moderate-to-Severe Atopic Dermatitis
NCT03054428Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Mar 2017
- Primary completion
- Apr 2018
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of dupilumab in atopic dermatitis (AD), sponsored by Regeneron Pharmaceuticals. Started Mar 2017; status: completed.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03054428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03054428.